CN110846313B - Long-chain non-coding RNA XLOC _025806 and application thereof in human umbilical vein endothelial cells - Google Patents
Long-chain non-coding RNA XLOC _025806 and application thereof in human umbilical vein endothelial cells Download PDFInfo
- Publication number
- CN110846313B CN110846313B CN201911079078.6A CN201911079078A CN110846313B CN 110846313 B CN110846313 B CN 110846313B CN 201911079078 A CN201911079078 A CN 201911079078A CN 110846313 B CN110846313 B CN 110846313B
- Authority
- CN
- China
- Prior art keywords
- endothelial cells
- human umbilical
- umbilical vein
- vein endothelial
- xloc
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 210000002889 endothelial cell Anatomy 0.000 title claims abstract description 116
- 210000003606 umbilical vein Anatomy 0.000 title claims abstract description 108
- 108091027963 non-coding RNA Proteins 0.000 title claims abstract description 29
- 102000042567 non-coding RNA Human genes 0.000 title claims abstract description 29
- 230000030279 gene silencing Effects 0.000 claims abstract description 34
- 230000035755 proliferation Effects 0.000 claims abstract description 27
- 230000006907 apoptotic process Effects 0.000 claims abstract description 25
- 230000015572 biosynthetic process Effects 0.000 claims abstract description 18
- 210000005239 tubule Anatomy 0.000 claims abstract description 18
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 16
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 15
- 230000001737 promoting effect Effects 0.000 claims abstract description 11
- 108020005198 Long Noncoding RNA Proteins 0.000 claims abstract 8
- 108091046869 Telomeric non-coding RNA Proteins 0.000 claims description 73
- 210000004027 cell Anatomy 0.000 claims description 29
- 239000013604 expression vector Substances 0.000 claims description 12
- 238000000338 in vitro Methods 0.000 claims description 12
- 239000003795 chemical substances by application Substances 0.000 claims description 10
- 238000003259 recombinant expression Methods 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 8
- 239000002299 complementary DNA Substances 0.000 claims description 6
- 230000005764 inhibitory process Effects 0.000 claims description 6
- 239000002773 nucleotide Substances 0.000 claims description 5
- 125000003729 nucleotide group Chemical group 0.000 claims description 5
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 230000003584 silencer Effects 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 21
- 230000002018 overexpression Effects 0.000 abstract description 18
- 239000013598 vector Substances 0.000 abstract description 15
- 230000033115 angiogenesis Effects 0.000 abstract description 10
- 230000008569 process Effects 0.000 abstract description 7
- 230000001105 regulatory effect Effects 0.000 abstract description 5
- 238000010353 genetic engineering Methods 0.000 abstract description 4
- 230000006870 function Effects 0.000 description 11
- 239000000243 solution Substances 0.000 description 9
- 238000005406 washing Methods 0.000 description 8
- 239000001963 growth medium Substances 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 108010082117 matrigel Proteins 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 5
- 108010040476 FITC-annexin A5 Proteins 0.000 description 5
- 230000033228 biological regulation Effects 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 230000029087 digestion Effects 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 108090000672 Annexin A5 Proteins 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 238000012258 culturing Methods 0.000 description 4
- 230000014509 gene expression Effects 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 238000010186 staining Methods 0.000 description 4
- 102000004121 Annexin A5 Human genes 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- 238000012408 PCR amplification Methods 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 238000002123 RNA extraction Methods 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000031018 biological processes and functions Effects 0.000 description 2
- 238000007664 blowing Methods 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 239000006143 cell culture medium Substances 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000004528 endothelial cell apoptotic process Effects 0.000 description 2
- 238000001976 enzyme digestion Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 229920002113 octoxynol Polymers 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 206010047139 Vasoconstriction Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 230000034303 cell budding Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 108091092328 cellular RNA Proteins 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000004042 decolorization Methods 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000010339 dilation Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 238000007667 floating Methods 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 238000012165 high-throughput sequencing Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 210000001711 oxyntic cell Anatomy 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 238000012342 propidium iodide staining Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000014493 regulation of gene expression Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000007651 self-proliferation Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 239000012192 staining solution Substances 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 239000012089 stop solution Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000003151 transfection method Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 230000025033 vasoconstriction Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/069—Vascular Endothelial cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/65—MicroRNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Vascular Medicine (AREA)
- Cell Biology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The invention discloses a long-chain non-coding RNA XLOC _025806 and application thereof in human umbilical vein endothelial cells. The invention detects the overexpression vector and silencing reagent lncRNA XLOC _025806Silencer which exogenously synthesize lncRNA XLOC _025806 by genetic engineering technology, detects the proliferation and apoptosis conditions of human umbilical vein endothelial cells after overexpression/silencing lncRNA XLOC _025806, and the result proves that lncRNA XLOC _025806 can participate in the processes of inhibiting the proliferation of human umbilical vein endothelial cells, promoting the apoptosis of human umbilical vein endothelial cells and promoting the formation of endothelial cell external tubules, and further indicates that lncRNA XLOC _025806 participates in the process of angiogenesis by regulating the function of human umbilical vein endothelial cells.
Description
Technical Field
The invention belongs to the technical field of cell engineering and genetic engineering, and particularly relates to long-chain non-coding RNA XLOC _025806 and application thereof in human umbilical vein endothelial cells.
Background
Angiogenesis (Angiogenesis) refers to the development of new blood vessels from existing capillaries or postcapillary veins, mainly involving the proliferation, budding and migration of vascular endothelial cells, a very complex biological process that depends on the subtle regulation of gene expression and also requires the co-participation of multiple factors.
Human Umbilical Vein Endothelial Cells (HUVECs) are specialized epithelial Cells consisting of a layer of flattened Cells that form the inner wall of a blood vessel. Endothelial cells have a variety of biological functions including angiogenesis, arteriosclerosis, control of vasoconstriction and dilation, and the like. The endothelial cells have the potential of stem cells, can be transmitted for 50-60 generations theoretically, and have very important relation with angiogenesis, namely the self-proliferation capacity of the endothelial cells can directly influence the angiogenesis, so the endothelial cells are ideal cells for researching the formation of blood vessels.
Long non-coding RNA (lncRNA) is a type of non-coding RNA with a length of more than 200 nt. Research shows that lncRNA is widely involved in biological processes, can be involved in gene expression regulation from an apparent modification level, a transcription level and a post-transcription level, and further plays an important role in the processes of proliferation, differentiation, survival and transfer of cells. However, no report about the regulation of the expression change of lncRNA XLOC _025806 on the function of human umbilical vein endothelial cells is available at home and abroad at present.
Disclosure of Invention
The primary objective of the present invention is to overcome the disadvantages and drawbacks of the prior art and to provide a long non-coding RNA XLOC _ 025806.
Another object of the invention is to provide a silencing agent that inhibits the function of lncRNA XLOC _ 025806.
Still another objective of the invention is to provide the application of the long-chain non-coding RNA XLOC _025806 or the silencing agent for inhibiting the function of lncRNA XLOC _025806 in human umbilical vein endothelial cells. The expression level of lncRNA XLOC _025806 in human umbilical vein endothelial cells is changed by a genetic engineering technology, and the application of the lncRNA XLOC _025806 in regulating and controlling the proliferation, apoptosis and angiogenesis of the human umbilical vein endothelial cells is determined.
The purpose of the invention is realized by the following technical scheme:
a long non-coding RNA XLOC _025806(lncRNA XLOC _025806) having a nucleotide sequence set forth in SEQ ID NO: 1 is shown.
A silencing agent for inhibiting the function of the long non-coding RNA XLOC _025806 is lncRNA XLOC _025806Silencer, and the nucleotide sequence of the silencing agent is shown as follows (SEQ ID NO: 2):
GAGACGAATTATCAAATACCACTTGGATTGAACACTGATGAAGCAAGCATGGATTGACTTCAGCCACAGCAACCCAGACCATTTTCTTTCACCCACCAACCCTAGCCTTTACTGACC。
a recombinant expression vector comprising said long non-coding RNA XLOC _ 025806.
A recombinant cell, wherein the recombinant expression vector or the silencing agent for inhibiting the function of the long-chain non-coding RNA XLOC _025806 is transfected into a human umbilical vein endothelial cell.
The application of the long-chain non-coding RNA XLOC _025806 or the silencing agent for inhibiting the function of the long-chain non-coding RNA XLOC _025806 in human umbilical vein endothelial cells is in an in vitro environment.
The long-chain non-coding RNA XLOC _025806 inhibits the proliferation of human umbilical vein endothelial cells, promotes the apoptosis of the human umbilical vein endothelial cells, and promotes the human umbilical vein endothelial cells to form in-vitro tubules, and the lncRNA XLOC _025806 participates in the angiogenesis process by regulating the functions of the human umbilical vein endothelial cells.
The inhibition of proliferation of human umbilical vein endothelial cells, the promotion of apoptosis of the human umbilical vein endothelial cells and the promotion of the formation of external tubules of the human umbilical vein endothelial cells are realized by adding exogenous long-chain non-coding RNA XLOC _ 025806.
The addition of exogenous long-chain non-coding RNA XLOC _025806 is realized by the following steps: the long-chain non-coding RNA XLOC _025806 is connected to pcDNA3.1(-) vector to construct a super-expression vector of the long-chain non-coding RNA XLOC _025806, and then the super-expression vector is transfected into human umbilical vein endothelial cells.
The overexpression vector of the long-chain non-coding RNA XLOC _025806 is preferably constructed by the following method: carrying out PCR amplification by taking human umbilical vein endothelial cell cDNA as a template and taking lncRNA-F and lncRNA-R as primers to obtain lncRNA XLOC _ 025806; then carrying out double enzyme digestion by KpnI and NheI enzymes, recovering and connecting to a pcDNA3.1(-) vector to obtain a super expression vector of the long-chain non-coding RNA XLOC _ 025806; wherein the nucleotide sequences of lncRNA-F and lncRNA-R are shown as follows:
lncRNA-F:CTAGCTAGCTAGCAATGCTAGATCTTTAACCCACTGA;
lncRNA-R:CGGGGTACCCCGATGGATCCTTTAATCAATTGCCTGG。
the silencing reagent for inhibiting the function of the long-chain non-coding RNA XLOC _025806 promotes the proliferation of human umbilical vein endothelial cells, inhibits the apoptosis of the human umbilical vein endothelial cells and inhibits the human umbilical vein endothelial cells from forming external tubules.
The promotion of the proliferation of the human umbilical vein endothelial cells, the inhibition of the apoptosis of the human umbilical vein endothelial cells and the inhibition of the formation of the external tubules of the human umbilical vein endothelial cells are realized by transferring exogenous lncRNA XLOC _025806Silencer, namely, lncRNA XLOC _025806Silencer is directly transfected into the human umbilical vein endothelial cells.
The long-chain non-coding RNA XLOC _025806 is applied to drugs for inhibiting and promoting the proliferation of human umbilical vein endothelial cells, promoting the apoptosis of the human umbilical vein endothelial cells and/or promoting the human umbilical vein endothelial cells to form in-vitro tubules.
The medicine contains a sequence of long-chain non-coding RNA XLOC _025806 and/or contains a recombinant expression vector.
The recombinant expression vector contains a sequence of long-chain non-coding RNA XLOC _025806, and can express long-chain non-coding RNA XLOC _025806 in human umbilical vein endothelial cells; preferably, the construction is carried out by the following method: carrying out PCR amplification by taking human umbilical vein endothelial cell cDNA as a template and taking lncRNA-F and lncRNA-R as primers to obtain lncRNA XLOC _ 025806; then carrying out double enzyme digestion by KpnI and NheI enzymes, recovering and connecting to a pcDNA3.1(-) vector to obtain a recombinant expression vector; wherein the nucleotide sequences of lncRNA-F and lncRNA-R are shown as follows:
lncRNA-F:CTAGCTAGCTAGCAATGCTAGATCTTTAACCCACTGA;
lncRNA-R:CGGGGTACCCCGATGGATCCTTTAATCAATTGCCTGG。
the silencing reagent for inhibiting the function of the long-chain non-coding RNA XLOC _025806 is applied to the preparation of medicaments for promoting the proliferation of human umbilical vein endothelial cells, inhibiting the apoptosis of the human umbilical vein endothelial cells and/or inhibiting the formation of external tubules of the human umbilical vein endothelial cells.
The medicine contains a sequence of lncRNA XLOC _025806Silencer, and can inhibit the expression of long-chain non-coding RNA XLOC _025806 in human umbilical vein endothelial cells.
The verification results of the invention are as follows:
1. according to the invention, the proliferation condition of the human umbilical vein endothelial cells is detected by an EdU method, and the proliferation rate of the human umbilical vein endothelial cells is obviously reduced (P <0.05) compared with a control group (pcDNA3.1) after the lncRNA XLOC _025806 is over-expressed (figure 1). After silencing lncRNA XLOC _025806, the proliferation rate of human umbilical vein endothelial cells was very significantly increased (P <0.01) compared to the control (NC) (fig. 2).
2. The apoptosis condition of the human umbilical vein endothelial cells is detected by an Annexin V-FITC/PI technology, and the apoptosis rate of the human umbilical vein endothelial cells is remarkably increased (P is less than 0.01) compared with a control group (pcDNA3.1) after the lncRNA XLOC _025806 is over-expressed (figure 3). After silencing lncRNA XLOC _025806, the proliferation rate of human umbilical vein endothelial cells was significantly decreased (P <0.05) compared to the control group (NC) (fig. 4).
3. In the invention, Matrigel is used as a carrier to simulate in vitro tubule formation, and the tube formation number of human umbilical vein endothelial cells is remarkably increased (P <0.01) compared with that of a control group (Blank) after the lncRNA XLOC _025806 is over-expressed (FIG. 5). After silencing lncRNA XLOC _025806, the tube count of human umbilical vein endothelial cells was very significantly reduced (P <0.01) compared to the Blank control (Blank) (fig. 6).
The invention takes lncRNA XLOC _025806(SEQ ID NO: 1) as a research object, adopts a molecular cell biology method to research the application of the lncRNA XLOC _025806 in human umbilical vein endothelial cells, and proves the effect of lncRNA XLOC _025806 on the human umbilical vein endothelial cells for the first time. The overexpression and silencing of lncRNA XLOC _025806 prove that lncRNA XLOC _025806 can be involved in inhibiting the proliferation of human umbilical vein endothelial cells, promoting the apoptosis of the human umbilical vein endothelial cells and promoting the formation of endothelial cell in vitro tubules, and further shows that lncRNA XLOC _025806 is involved in the angiogenesis process by regulating the function of the human umbilical vein endothelial cells.
Compared with the prior art, the invention has the following advantages and effects:
the invention detects the overexpression vector and the silencing reagent which are exogenously synthesized into lncRNA XLOC _025806 by the genetic engineering technology, detects the proliferation and apoptosis conditions of human umbilical vein endothelial cells after overexpression/silencing of lncRNA XLOC _025806, and is a molecular mechanism accumulation material for lncRNA to regulate and control the human umbilical vein endothelial cells. Meanwhile, the results of the invention show that lncRNA XLOC _025806 promotes the formation of endothelial cell tubules in vitro, and further show that lncRNA XLOC _025806 can participate in the angiogenesis process by regulating the function of human umbilical vein endothelial cells.
Drawings
FIG. 1 is a graph showing the result of EdU method detecting the regulation of human umbilical vein endothelial cell proliferation after overexpression of lncRNA XLOC _ 025806.
FIG. 2 is a graph showing the result of EdU method detecting the regulation of human umbilical vein endothelial cell proliferation after silencing lncRNA XLOC _ 025806.
FIG. 3 is a graph showing the results of the Annexin V-FITC method for detecting the apoptosis of human umbilical vein endothelial cells after overexpression of lncRNA XLOC _ 025806.
FIG. 4 is a graph showing the results of the Annexin V-FITC method for detecting the regulation of human umbilical vein endothelial cell apoptosis after the silencing of IncRNA XLOC _ 025806.
FIG. 5 is a graph of matrigel vascularization assay results of human umbilical vein endothelial cell vascularization after overexpression of lncRNA XLOC _ 025806.
FIG. 6 is a graph of matrigel vascularization assay results of in vitro vascularization of human umbilical vein endothelial cells following silencing of lncRNA XLOC _ 025806.
Detailed Description
The present invention will be described in further detail with reference to examples, but the embodiments of the present invention are not limited thereto. It should be understood that the embodiments described in this specification are only for the purpose of illustrating the invention and are not to be construed as limiting the invention, and the parameters, proportions and the like of the embodiments may be suitably selected without materially affecting the results. The examples are all reagents and process steps conventional in the art, except where specifically indicated.
The base sequence related by the invention is shown as SEQ ID NO: the long non-coding RNA shown in 1 is an lncRNA found for the first time by constructing a small pig myocardial infarction model, performing RNA high-throughput sequencing and performing biological information analysis, wherein the human genome also contains the sequence, the full-length sequence is 819bp, the long non-coding RNA is named lncRNA XLOC _025806, and the sequence is shown as follows:
lncRNA XLOC_025806(SEQ ID NO:1):
UUUUUUUUCUUUUUUCUUUUUAGAGCUGCACCUGCAGCAUAUCAAGGUUCCCAGGCUAGGGGUCAAAUCGGAGCUGUAGCUGCUGGCCUAUGCCACAGCUUCAGCCACAGCAACCCAGGAUCUGAGCCACGCCUGUGACCUACACCACAGCUCACGGCAAUGCUAGAUCUUUAACCCACUGAGUGAGGCCAGGGAUCAAACCCACAUCCUCAUGGGUACUAGUUGGAUUCGUUUCUGCUGUGCCACAGUGGAAACUCUUAUAAUAACUUUAAUUUUGUUGAUAAUUGUGCUUGCCUUCCUAAAAUUUACAACUAUUUAGAGAUAAAUUUGAAGAGACGAAUUAUCAAAUACAUAUAUGGCUGUUAUUGGAAGUCAAGUGAUGCUGAGUAGCCAAAAGCCAAAUGUCUACUACACAUAUGAAGUAUUUGGAGACCGUUGCCUUAUGUCCCCUGAAACUGAUAAUUUUAAGUUUAAACAUACCAUUUUCUUUCACCCACCCCUAAUACCAAUGUCUCCUUUCAUGAUGGCCCCUAGGCAGACUGAGCACAACAAGCUCUGAAGCAAGCAUGGAUUGAUGUCACUUGGAUUGAACACUGAAGACACUGAAAACCCUAGCCUUUACUGACCUUCAGAGAAAGUCAUUGCUUGAGUUCCUGCUGUGGCACAGUGGAUUAAGAAUCUGACUGCAUCAGCUAGGGUUGCUCUGAAGGUGUAGGUUUGAUCCUCAGCCCAGGCAAUUGAUUAAAGGAUCCAUUGUUGCCACAACUGCAGCAUAGGUCACAGCUGUGGCUCAGGUCAGUCCCUGGCUUGGGAACUUCC。
EXAMPLE 1 cellular RNA extraction and reverse transcription
RNA extraction of human umbilical vein endothelial cells (purchased from ScienCell) the following procedure was followed according to the instructions of TRIzol of Takara:
(1) culturing human umbilical vein endothelial cells to proper density, discarding culture medium, washing cells twice with PBS, and washing every 10cm21mL of TRIzol is directly added into the bottom area of the cell culture plate;
(2) standing on ice for 10min to fully lyse the tissue/cells, centrifuging at 4 ℃ and 12000rpm for 5min, discarding the precipitate, and taking the supernatant into a new 1.5mL RNase-free tube;
(3) adding 200 mu L chloroform (1 mL of TRIzol) and shaking vigorously for 15-30 s, standing on ice for 15min, and centrifuging at 12000rpm at 4 ℃ for 15 min;
(4) absorbing the upper aqueous phase and placing the upper aqueous phase in a new 1.5mL RNase-free EP tube;
(5) adding 0.5mL of isopropanol (every 1mL of TRIzol), gently inverting and mixing, standing on ice for 10min, and centrifuging at 12000rpm at 4 ℃ for 10 min;
(6) discarding the supernatant, placing at room temperature, adding 1mL of 75% (v/v) ethanol-DEPC (per 1mL of TRIzol) along the tube wall to wash RNA, centrifuging at 12000rpm at 4 ℃ for 5min, and discarding the supernatant;
(7) vacuum drying for 5-10 min, and taking care to avoid excessive drying of RNA precipitate;
(8) DEPC water was added to dissolve the RNA pellet.
First Strand cDNA Synthesis was performed with reference to SuperScriptTM First-Strand Synthesis System for RT-PCR kit from Thermo.
Example 2 construction of a overexpression vector for lncRNA XLOC 025806
(1) The sequence of lncRNA XLOC _025806 was found to have no restriction sites for both KpnI and NheI by DNMAN software analysis, whereas the KpnI and NheI restriction sites were found in pcDNA3.1(-) vector (available from Invitrogen).
(2) Primer5.0 software designed lncRNA XLOC _025806 primers with addition of KpnI and NheI cleavage site sequences to its upstream and downstream primers, respectively. Wherein the primer sequence is as follows (5 '-3'):
lncRNA-F:CTAGCTAGCTAGCAATGCTAGATCTTTAACCCACTGA;
lncRNA-R:CGGGGTACCCCGATGGATCCTTTAATCAATTGCCTGG。
(3) using human umbilical vein endothelial cell cDNA (obtained by the method of example 1) as a template, the cDNA with the full length of lncRNA XLOC _025806 obtained by PCR amplification is subjected to gel recovery and purification, double digestion, recovery, connection with pcDNA3.1(-) vector, transformation, screening, sequencing and identification, and then endotoxin-free plasmid (the endotoxin-free plasmid miniprep kit is purchased from Magen) is extracted and named pcDNA3.1-lncRNA XLOC _ 025806.
EXAMPLE 3 culture of human umbilical vein endothelial cells
(1) Placing a cryopreserved tube filled with human umbilical vein endothelial cells (purchased from ScienCell) taken out of a liquid nitrogen tank in a 37 ℃ water bath to rapidly melt the cryopreserved tube;
(2) transferring the cells into a centrifuge tube, centrifuging at room temperature at 1000rpm for 5min, and pouring off the supernatant;
(3) adding preheated PBS for cleaning, centrifuging and pouring out the PBS;
(4) preparing an ECM complete medium: 93% (w/w) endothelial cell culture medium ECM (purchased from ScienCell corporation) + 5% (w/w) FBS (fetal bovine serum) + 1% (w/w) endothelial cell growth supplement ECGS (purchased from ScienCell corporation) + 1% (w/w) diabody;
(5) adding ECM to suspend the cells in a full culture medium, and inoculating the cells into a culture flask; standing at 37 deg.C for 5% CO2And (5) standing and culturing in an incubator.
The double-resistant is penicillin and streptomycin.
Example 4 seeding and transfection of human umbilical vein endothelial cells
(1) When the density of human umbilical vein endothelial cells reaches about 90%, pouring out the culture medium, and washing the cells for 2 times by using preheated PBS;
(2) adding 0.25% trypsin for digestion for 5min, observing most cells floating under a microscope, and immediately adding an equal amount of ECM complete culture medium (the configuration method is the same as the step (4) of the example 2) to terminate digestion;
(3) blowing down the parietal cells by using a gun head, uniformly blowing, transferring the cell suspension into a centrifuge tube, centrifuging at 1000rpm for 5min, and pouring out the supernatant;
(4) adding PBS to clean for 2 times, centrifuging at 1000rpm for 5 min;
(5) gently resuspending the cell pellet with ECM complete medium, uniformly distributing into each well, supplementing volume with ECM complete medium, gently shaking, and culturing in an incubator;
(6) observing the cell state after about 24 hours, and preparing for transfection when the confluence degree of the cells reaches about 75-90%;
(8) the transfected cells were placed at 37 ℃ in 5% CO2Continuously culturing in an incubator;
(9) and after 24-48 h of transfection, observing the cell state, and collecting the cells after good growth.
Example 5 human umbilical vein endothelial cell proliferation assay
The experiment for detecting Cell proliferation by the EdU method in the invention refers to Cell-Light of Ruibo Biotech Co., Ltd, Guangzhou CityTMEdU Apollo 567In vitro Kit. The method comprises the following specific steps (taking a 48-hole plate as an example):
(1) diluting the EdU solution with endothelial cell culture medium (ECM complete medium, prepared in the same manner as in step (4) of example 2) at a volume ratio of 1000:1 to prepare a suitable amount of 50. mu.M EdU medium;
(2) adding 200 mu L of 50 mu M EdU culture medium into each hole, incubating for 2h, and removing the culture medium;
(3) washing cells with 200 μ L PBS per well for 5min for 2 times by decolorizing and shaking table;
(4) adding 100 μ L of cell fixing solution (PBS containing 4% paraformaldehyde) into each well, incubating at room temperature for 30min, and discarding the waste solution;
(5) adding 100 mu L of glycine with the concentration of 2mg/mL into each hole, and removing the glycine solution after incubating for 5min by a decoloring shaker;
(6) adding 200 μ L PBS into each well, washing for 5min by a decoloring shaker, and discarding the PBS;
(7) incubating 200 μ L of penetrant (0.5% (v/v) Triton X in PBS) per well in a decolorization shaker for 10min, and washing with PBS for 5 min;
(8) adding 200 mu L of 1 XApollo staining reaction solution into each hole, incubating for 30min at room temperature in a dark place, and removing the staining reaction solution;
(9) adding 200 μ L of penetrant (0.5% (v/v) Triton X PBS) into each well, washing for 10min for 2 times by decolorizing shaker, and discarding penetrant;
(10) diluting the reagent F by deionized water according to the volume ratio of 100:1, preparing a proper amount of 1 × Hoechst3342 reaction solution, and storing in the dark;
(11) adding 200 μ L of 1 × Hoechst3342 reaction solution (Hoechst) into each well, incubating at room temperature in dark for 30min, and removing the staining reaction solution;
(12) washing 2 times by adding 200 μ L PBS per well;
(13) adding 200 mu L PBS into each hole for storage;
(14) after the staining was completed, a photograph was taken with a fluorescence microscope.
Example 6 human umbilical vein endothelial cell apoptosis assay
The invention uses Annexin V-FITC/PI technology to detect Apoptosis, and the specific operation steps are as follows according to the specification of FITC Annexin V Apoptosis Detection Kit with PI Kit of Guangzhou Korea Biotechnology Limited company:
(1) placing the cell culture plate at room temperature, slightly rinsing cells in the culture plate by using PBS, and removing the PBS;
(2) adding 0.25% trypsin for digestion for 5min, observing most cells under a microscope, immediately adding an equal amount of stop solution (namely ECM complete culture medium; the preparation method is the same as the step (4) of the example 2) to stop digestion;
(3) cells were collected by centrifugation at 1000rpm for 5min, the supernatant was discarded, and the cells were washed twice with pre-cooled PBS. Adjusting the number of cells per tube to be (0.2-1.0) × 106500 μ L of 1 × Annexin V Buffer was added to gently resuspend the cells;
(4) adding 5 μ L Annexin V-FITC and 5 μ L propidium iodide staining solution, and mixing gently;
(5) after incubation for 15min at room temperature in the dark, flow cytometry analysis was carried out immediately.
Example 7 tubule formation experiment
(1) Placing the Matrigel in a refrigerator at 4 ℃ for overnight melting, and placing a 48-hole plate and a gun head in the refrigerator at 4 ℃ for precooling overnight;
(2) adding 100 mu L of Matrigel to a 48-hole plate in each hole to ensure that the gel completely covers the bottom of the hole, avoiding bubbles generated in the adding process and operating on ice;
(3) incubating at 37 ℃ for 1 h;
(4) digesting human umbilical vein endothelial cells to ensure that each hole has 2 to 3 ten thousand cells;
(5) incubating for 2-8 h at 37 ℃, observing at any time, finishing photographing within 10h, and calculating the number of complete lumens.
Analysis of results
1. And (4) recovering the frozen human umbilical vein endothelial cells and carrying out subculture. The invention exogenously synthesizes lncRNA XLOC _025806 overexpression vector (pcDNA3.1-lncRNA XLOC _025806) and silencing reagent lncRNA XLOC _025806Silencer by gene engineering technology, transfects the overexpression vector to human umbilical vein endothelial cells, and detects the proliferation condition of the human umbilical vein endothelial cells after 24h by referring to an EdU kit instruction. The detection result shows that: after overexpression of lncRNA XLOC _025806, the proliferation rate of human umbilical vein endothelial cells was significantly decreased (P <0.05) (FIG. 1) compared to the control group (pcDNA3.1(-)), and after silencing of lncRNA XLOC _025806, the proliferation rate of human umbilical vein endothelial cells was significantly increased (P <0.01) (FIG. 2) compared to the control group (NC).
The silencing reagent lncRNA XLOC _025806Silencer is synthesized by Ruibo Biotechnology Ltd, Guangzhou, and has the nucleotide sequence shown as (SEQ ID NO: 2) (the same below):
GAGACGAATTATCAAATACCACTTGGATTGAACACTGATGAAGCAAGCATGGATTGACTTCAGCCACAGCAACCCAGACCATTTTCTTTCACCCACCAACCCTAGCCTTTACTGACC。
2. and (4) recovering the frozen human umbilical vein endothelial cells and carrying out subculture. The invention exogenously synthesizes lncRNA XLOC _025806 overexpression vector (pcDNA3.1-lncRNA XLOC _025806) and silencing reagent (lncRNA XLOC _025806Silencer) by gene engineering technology, transfects the overexpression vector and the silencing reagent to human umbilical vein endothelial cells, and detects the Apoptosis condition of the human umbilical vein endothelial cells after 48 hours by referring to FITC Annexin V Apoptosis Detection Kit with PI specification. The test results show that after the lncRNA XLOC _025806 is over-expressed, the apoptosis rate of the human umbilical vein endothelial cells is greatly increased (P <0.01) compared with that of a control group (pcDNA3.1 (-)))) (FIG. 3), and after the lncRNA XLOC _025806 is silenced, the proliferation rate of the human umbilical vein endothelial cells is significantly reduced (P <0.05) compared with that of a control group (NC) (synthesized by Ruibo Biotechnology, Inc., Guangzhou) (FIG. 4).
3. And (4) recovering the frozen human umbilical vein endothelial cells and carrying out subculture. The invention exogenously synthesizes lncRNA XLOC _025806 overexpression vector (pcDNA3.1-lncRNA XLOC _025806) and silencing reagent (lncRNA XLOC _025806Silencer) by gene engineering technology, and transfects the overexpression vector and the silencing reagent to human umbilical vein endothelial cells. The tube formation of human umbilical vein endothelial cells was tested by simulating in vitro tubule formation with Matrigel as a carrier, and it was found that the tube formation of human umbilical vein endothelial cells was significantly increased (P <0.01) compared to the Blank control (Blank) after overexpression of lncRNA XLOC _025806 (FIG. 5). After silencing lncRNA XLOC _025806, the tube count of human umbilical vein endothelial cells was very significantly reduced (P <0.01) compared to the Blank control (Blank) (fig. 6).
The above embodiments are preferred embodiments of the present invention, but the present invention is not limited to the above embodiments, and any other changes, modifications, substitutions, combinations, and simplifications which do not depart from the spirit and principle of the present invention should be construed as equivalents thereof, and all such changes, modifications, substitutions, combinations, and simplifications are intended to be included in the scope of the present invention.
Sequence listing
<110> southern China university of agriculture
Guangdong province laboratory animal monitoring station
<120> long non-coding RNA XLOC _025806 and application thereof in human umbilical vein endothelial cells
<160> 4
<170> SIPOSequenceListing 1.0
<210> 1
<211> 819
<212> RNA
<213> Artificial Sequence (Artificial Sequence)
<220>
<223> lncRNA XLOC_025806
<400> 1
uuuuuuuucu uuuuucuuuu uagagcugca ccugcagcau aucaagguuc ccaggcuagg 60
ggucaaaucg gagcuguagc ugcuggccua ugccacagcu ucagccacag caacccagga 120
ucugagccac gccugugacc uacaccacag cucacggcaa ugcuagaucu uuaacccacu 180
gagugaggcc agggaucaaa cccacauccu cauggguacu aguuggauuc guuucugcug 240
ugccacagug gaaacucuua uaauaacuuu aauuuuguug auaauugugc uugccuuccu 300
aaaauuuaca acuauuuaga gauaaauuug aagagacgaa uuaucaaaua cauauauggc 360
uguuauugga agucaaguga ugcugaguag ccaaaagcca aaugucuacu acacauauga 420
aguauuugga gaccguugcc uuaugucccc ugaaacugau aauuuuaagu uuaaacauac 480
cauuuucuuu cacccacccc uaauaccaau gucuccuuuc augauggccc cuaggcagac 540
ugagcacaac aagcucugaa gcaagcaugg auugauguca cuuggauuga acacugaaga 600
cacugaaaac ccuagccuuu acugaccuuc agagaaaguc auugcuugag uuccugcugu 660
ggcacagugg auuaagaauc ugacugcauc agcuaggguu gcucugaagg uguagguuug 720
auccucagcc caggcaauug auuaaaggau ccauuguugc cacaacugca gcauagguca 780
cagcuguggc ucaggucagu cccuggcuug ggaacuucc 819
<210> 2
<211> 117
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<220>
<223> lncRNA XLOC_025806 Silencer
<400> 2
gagacgaatt atcaaatacc acttggattg aacactgatg aagcaagcat ggattgactt 60
cagccacagc aacccagacc attttctttc acccaccaac cctagccttt actgacc 117
<210> 3
<211> 37
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<220>
<223> lncRNA-F
<400> 3
ctagctagct agcaatgcta gatctttaac ccactga 37
<210> 4
<211> 37
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<220>
<223> lncRNA-R
<400> 4
cggggtaccc cgatggatcc tttaatcaat tgcctgg 37
Claims (10)
1. A long non-coding RNA XLOC _025806, characterized by: the nucleotide sequence is shown as SEQ ID NO: 1 is shown.
2. A silencing agent that inhibits the function of long non-coding RNA XLOC _025806 of claim 1, wherein: the silencing reagent is lncRNA XLOC _025806Silencer, and the nucleotide sequence of the silencing reagent is shown in SEQ ID NO: 2, respectively.
3. A recombinant expression vector comprising the cDNA sequence of long non-coding RNA XLOC _025806 of claim 1.
4. A recombinant cell, wherein: to transfect the recombinant expression vector of claim 3 or the silencing agent of claim 2 into human umbilical vein endothelial cells.
5. The use of the long non-coding RNA XLOC _025806 of claim 1 or the silencing agent of claim 2 that inhibits the function of long non-coding RNA XLOC _025806 in human umbilical vein endothelial cells, wherein:
the environment of the application is an in vitro environment;
the long-chain non-coding RNA XLOC _025806 inhibits the proliferation of human umbilical vein endothelial cells, promotes the apoptosis of the human umbilical vein endothelial cells, and promotes the human umbilical vein endothelial cells to form in-vitro tubules;
the silencing reagent for inhibiting the function of the long-chain non-coding RNA XLOC _025806 promotes the proliferation of human umbilical vein endothelial cells, inhibits the apoptosis of the human umbilical vein endothelial cells and inhibits the human umbilical vein endothelial cells from forming external tubules.
6. Use according to claim 5, characterized in that:
the inhibition of proliferation of human umbilical vein endothelial cells, the promotion of apoptosis of the human umbilical vein endothelial cells and the promotion of the formation of external tubules of the human umbilical vein endothelial cells are realized by adding exogenous long-chain non-coding RNA XLOC _ 025806;
the promotion of the proliferation of the human umbilical vein endothelial cells, the inhibition of the apoptosis of the human umbilical vein endothelial cells and the inhibition of the formation of external tubules of the human umbilical vein endothelial cells are realized by transferring exogenous lncRNA XLOC-025806 Silenecer.
7. The use of the long non-coding RNA XLOC _025806 of claim 1 in the manufacture of a medicament for inhibiting proliferation of human umbilical vein endothelial cells, promoting apoptosis of human umbilical vein endothelial cells, and/or promoting formation of tubules in vitro in human umbilical vein endothelial cells.
8. Use according to claim 7, characterized in that:
the medicine contains a sequence of long-chain non-coding RNA XLOC _025806 and/or contains a recombinant expression vector;
the recombinant expression vector contains a cDNA sequence of long-chain non-coding RNA XLOC _ 025806.
9. The use of the silencing agent of claim 2 for inhibiting the function of long-chain non-coding RNA XLOC _025806 in the preparation of a medicament for promoting proliferation of human umbilical vein endothelial cells, inhibiting apoptosis of human umbilical vein endothelial cells, and/or inhibiting formation of tubules in vitro by human umbilical vein endothelial cells.
10. Use according to claim 9, characterized in that:
the medicine contains the sequence of lncRNA XLOC-025806 Silencer.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201911079078.6A CN110846313B (en) | 2019-11-07 | 2019-11-07 | Long-chain non-coding RNA XLOC _025806 and application thereof in human umbilical vein endothelial cells |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201911079078.6A CN110846313B (en) | 2019-11-07 | 2019-11-07 | Long-chain non-coding RNA XLOC _025806 and application thereof in human umbilical vein endothelial cells |
Publications (2)
Publication Number | Publication Date |
---|---|
CN110846313A CN110846313A (en) | 2020-02-28 |
CN110846313B true CN110846313B (en) | 2021-07-02 |
Family
ID=69599134
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201911079078.6A Expired - Fee Related CN110846313B (en) | 2019-11-07 | 2019-11-07 | Long-chain non-coding RNA XLOC _025806 and application thereof in human umbilical vein endothelial cells |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN110846313B (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114958849B (en) * | 2022-05-26 | 2023-10-27 | 华南农业大学 | Application of lncRNACACF to miR-520b-3p adsorption in regulation of human umbilical vein endothelial cell cycle |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110384800A (en) * | 2019-07-19 | 2019-10-29 | 广东省实验动物监测所 | Application of the LncRNA XLOC_075168 in the drug that preparation promotes angiogenesis |
CN110403954A (en) * | 2019-07-19 | 2019-11-05 | 广东省实验动物监测所 | Application of the inhibitor of LncRNA XLOC_110286 in the drug that preparation promotes angiogenesis |
-
2019
- 2019-11-07 CN CN201911079078.6A patent/CN110846313B/en not_active Expired - Fee Related
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110384800A (en) * | 2019-07-19 | 2019-10-29 | 广东省实验动物监测所 | Application of the LncRNA XLOC_075168 in the drug that preparation promotes angiogenesis |
CN110403954A (en) * | 2019-07-19 | 2019-11-05 | 广东省实验动物监测所 | Application of the inhibitor of LncRNA XLOC_110286 in the drug that preparation promotes angiogenesis |
Non-Patent Citations (2)
Title |
---|
Genbank Accession:NC_010456.5;Genbank database;《Genbank database》;20180112;第101268081-101268899位 * |
Long non-coding RNAs have age-dependent diurnal expression that coincides with age-related changes in genome-wide facultative heterochromatin.;Jinhee Park et al.;《BMC Genomics》;20181029;第19卷;e777(附加文件4) * |
Also Published As
Publication number | Publication date |
---|---|
CN110846313A (en) | 2020-02-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN110403954B (en) | Application of LncRNA XLOC _110286 inhibitor in preparation of medicine for promoting angiogenesis | |
CN110384800B (en) | Application of LncRNA XLOC _075168 in preparation of medicine for promoting angiogenesis | |
CN110846315B (en) | Long-chain non-coding RNA XLOC _102237 and application thereof in human umbilical vein endothelial cells | |
CN110484614B (en) | Application of LncRNA XLOC _057528 inhibitor in preparation of medicine for promoting angiogenesis | |
CN107663539A (en) | Circular rna circ PTGR1 purposes | |
CN110846313B (en) | Long-chain non-coding RNA XLOC _025806 and application thereof in human umbilical vein endothelial cells | |
CN111154763A (en) | Application of long-chain non-coding RNA lncMGPF in regulation and control of pig muscle development function | |
CN114854756B (en) | Application of miR-370 to regulation of GLI1 expression in porcine ovarian granulosa cells | |
CN102453716B (en) | Clone and application of pig skeletal muscle specificity expression gene alpha-actin promoters | |
CN112852818A (en) | Circular RNA hsa _ circ _0001550 and application thereof | |
CN109852680B (en) | Application of FGFR1 gene in porcine ovarian granulosa cells | |
CN114432452A (en) | Application of RNA Hsa _ circ _0063865 inhibitor in preparation of anti-esophageal squamous cell carcinoma drug | |
CN111748559B (en) | Application of CTNNB1 gene in porcine ovary granular cells | |
CN108913695B (en) | Application of ZEB1 in human heart fibroblast | |
WO2022213704A1 (en) | High-migration mesenchymal stem cell, and preparation method therefor and application thereof | |
CN114836424A (en) | IncRNA IFFD and application thereof in swine ovarian granulosa cells | |
CN109293764A (en) | Deer subfamily activin A albumen and its preparation and application | |
CN110106182B (en) | Application of p65 gene in porcine ovarian granulosa cells | |
CN105624159B (en) | A kind of siRNA and its application for people's EDIL3 gene | |
CN108659108B (en) | NAC transcription factor related to hardening of golden pear fruit tops | |
CN113388614A (en) | Application of RSPO2 gene in porcine ovarian granulosa cells | |
CN114958849B (en) | Application of lncRNACACF to miR-520b-3p adsorption in regulation of human umbilical vein endothelial cell cycle | |
CN107090451A (en) | A kind of long-chain non-coding RNA uc.77 and its application | |
CN111118007A (en) | Long non-coding RNA and application thereof in diagnosis/treatment of cervical cancer | |
CN110946877A (en) | Stem cell biological product for treating liver cirrhosis and preparation method and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20210702 |